• Home
  • Current Clients
  • Client List
  • Clients In the News
    • 2020 News Releases >
      • Aerial BioPharma JZP-110 Jan 2020
    • 2019 News Releases >
      • Emergo Therapeutics Aug 2019
      • Emergo Therapeutics May 2019
      • Emergo Therapeutics April 2019
      • Aerial BioPharma JZP-110 March 2019
    • 2018 News Releases >
      • Emergo Therapeutics 2018
    • 2017 News Releases >
      • Aerial BioPharma JZP-110 Dec
    • 2016 News Releases >
      • Target PharmaSolutions Nov
      • Target PharmaSolutions Oct
      • Arrivo BIoVentures
      • Contego Medical
    • 2015 News Releases >
      • Contego Medical
      • AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio
      • Chapel Hill’s Achelios reports promising test results
    • 2014 News Releases >
      • Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound
      • Aerial Hears a Cool Jazz $400M Wake-Up Call
    • 2013 News Releases >
      • TBJ 2013 Life Sciences Awards winners revealed
      • Aerial Biopharma Announces Closing of Second Tranche of Series A
    • 2012 News Releases >
      • Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
      • Aerial Biopbarma Receives FDA Orpban Drug Designation
      • A new migraine drug taken by skin? How Achelios could make it happen
      • Acorda 4Q profit climbs; company buying Neuronex
      • Addrenex Founders Sell Neuronex
    • 2011 News Releases >
      • Lookout Capital Announces Investment In EnviCor
  • Interests
  • Contact me
  KJA Associates, LLC - part-time CFO services

Chapel Hill’s Achelios reports promising test results
By David Raniidranii@newsobserver.com
03/24/2015 11:23 AM 03/24/2015 4:57 PM

Achelios Therapeutics, a startup drug-development company based in Chapel Hill, is reporting promising test results for its experimental topical treatment for migraine headaches.

Achelios announced Tuesday that a Phase 2a study of Topofen, a gel that permeates the skin and is applied over cranial nerves between the ear and the jaw, found that 45 percent of acute migraine sufferers enjoyed pain relief for 2 to 24 hours. That compares to 15 percent of patients treated by a placebo.

In addition, 50 percent of the patients who treated severe pain with Topofen were pain-free 24 hours later, versus 25 percent of placebo-treated patients.

The study involved 48 patients.

Related The crucial advantage of Topofen is that it avoids the side effects that plague oral migraine medications – gastric bleeding and ulcers, said Crist Frangakis, president and CEO.

Indeed, the active ingredient in Topofen is ketoprofen, a generic nonsteroidal anti-inflammatory drug that is available orally but is little-prescribed in the U.S. because of its side effects.

“The innovation we did was create a gel that allows the drug to permeate the skin with very high efficiency,” Frangakis said. The amount of ketoprofen in Toprofen is about one-tenth the amount used orally, he added.

Achelios, which was founded in 2012, has raised nearly $10 million from angel investors and has six full-time employees – three in Chapel Hill and three at its research lab in San Diego.

The company’s next step is conducting a larger Phase 2b study involving 100 to 200 patients that would be used to determine the optimum dosage.

But in order to do that, it needs to either raise additional funding – about $25 million is needed to take the drug all the way to the point that it could apply for regulatory approval – or team up with a large pharmaceutical company. Achelios is pursuing both options.

“It’s not good to rely on just one route,” Frangakis said

  • Home
  • Current Clients
  • Client List
  • Clients In the News
    • 2020 News Releases >
      • Aerial BioPharma JZP-110 Jan 2020
    • 2019 News Releases >
      • Emergo Therapeutics Aug 2019
      • Emergo Therapeutics May 2019
      • Emergo Therapeutics April 2019
      • Aerial BioPharma JZP-110 March 2019
    • 2018 News Releases >
      • Emergo Therapeutics 2018
    • 2017 News Releases >
      • Aerial BioPharma JZP-110 Dec
    • 2016 News Releases >
      • Target PharmaSolutions Nov
      • Target PharmaSolutions Oct
      • Arrivo BIoVentures
      • Contego Medical
    • 2015 News Releases >
      • Contego Medical
      • AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio
      • Chapel Hill’s Achelios reports promising test results
    • 2014 News Releases >
      • Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound
      • Aerial Hears a Cool Jazz $400M Wake-Up Call
    • 2013 News Releases >
      • TBJ 2013 Life Sciences Awards winners revealed
      • Aerial Biopharma Announces Closing of Second Tranche of Series A
    • 2012 News Releases >
      • Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
      • Aerial Biopbarma Receives FDA Orpban Drug Designation
      • A new migraine drug taken by skin? How Achelios could make it happen
      • Acorda 4Q profit climbs; company buying Neuronex
      • Addrenex Founders Sell Neuronex
    • 2011 News Releases >
      • Lookout Capital Announces Investment In EnviCor
  • Interests
  • Contact me